The COVID-19 Pandemic : (Record no. 25156)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 10632nam a22004573i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC6512661 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240724114950.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2021 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9789811481871 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9789811481857 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC6512661 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL6512661 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)1241445201 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RA644.C67 C68 2021 |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 614.592414 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Parveen, Shama. |
| 245 14 - TITLE STATEMENT | |
| Title | The COVID-19 Pandemic : |
| Remainder of title | Epidemiology, Molecular Biology and Therapy. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Singapore : |
| Name of producer, publisher, distributor, manufacturer | Bentham Science Publishers, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2021. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2021. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (276 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Foreword -- Preface -- List of Contributors -- An Introduction to Coronavirus Disease 2019 (COVID-19) -- Shama Parveen1,* and Sher Ali2 -- INTRODUCTION -- MORPHOLOGY, GENOME, PROTEINS AND VIRAL REPLICATION -- STRUCTURAL PROTEINS -- GLOBAL EPIDEMIOLOGY AND TRANSMISSION -- RISK FACTORS -- CLINICAL SYMPTOMS AND MANAGEMENT -- HOST IMMUNE RESPONSE AND PATHOGENESIS -- DIAGNOSTICS -- THERAPEUTICS (ANTIVIRALS AND NATURAL COMPOUNDS) -- VACCINE DEVELOPMENT -- CORONA WARRIORS -- SOCIO-ECONOMIC-ENVIRONMENTAL IMPACT -- CONCLUDING REMARKS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Morphology, Genomic Organization, Proteins and Replication of SARS-CoV-2 -- Nazim Khan1, Arshi Islam1, Abu Hamza1, Zoya Shafat1, Asimul Islam1, Anwar Ahmed2,3 and Shama Parveen1,* -- INTRODUCTION -- VIRAL MORPHOLOGY -- GENOMIC ORGANIZATION -- STRUCTURAL PROTEINS -- Spike Protein (S-protein) -- Envelope Protein (E-protein) -- Membrane Protein (M-protein) -- Nucleocapsid (N-protein) -- NON-STRUCTURAL PROTEINS -- VIRAL GENOME REPLICATION -- CONCLUDING REMARKS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Structural Protein Genes of SARS-CoV-2: Comprehensive Molecular Characterization -- Zoya Shafat1, Syed Abuzar Raza Rizvi2, Mohammad Misbah Urrehmaan1,2, Ayesha Tazeen1, Priyanka Sinha1, Anwar Ahmed3,4 and Shama Parveen1,* -- INTRODUCTION -- MATERIALS AND METHODS -- Sequences -- Compositional Properties -- Relative Synonymous Codon Usage (RSCU) -- Physiochemical Characterization -- Phylogenetic Analyses -- Dataset I -- Dataset II -- Dataset III -- Gene Ontology (GO) -- Mutational Analysis -- Selection Pressure Analysis -- Analysis of Entropy of Amino Acid Sequences -- RESULTS -- Nucleotide Composition Analysis -- S Gene -- E Gene. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | M Gene -- N Gene -- U- and A-ending Codons are Preferred in Coding Sequences -- S Gene -- E Gene -- M Gene -- N Gene -- Analysis of Protein Sequences -- Spike Protein -- Envelope Protein -- Membrane Protein -- Nucleocapsid Protein -- Phylogenetic Analysis -- Full Genome of Coronaviruses -- Structural Protein Genes of Coronaviruses -- Structural Protein Genes of Novel Coronaviruses (SARS-CoV-2) -- Computer Predicted Features -- Subcellular Localization Prediction with Functional Annotation -- Prediction of Effect of Mutations on Protein Function -- Helical Wheel Plot Analysis -- Analysis of Positive Selection -- S Dataset -- E Dataset -- M Dataset -- N Dataset -- Analysis of Entropy of Amino Acid Sequences -- DISCUSSION -- CONCLUDING REMARKS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Codon Based Characterization of S2 Subunit of Severe Acute Respiratory Syndrome-Related Coronaviruses -- Arshi Islam1, Nazish Parveen1, Md. Shakir Hussain Haider1, Ravins Dohare1, Anwar Ahmed2,3, Sher Ali1,4 and Shama Parveen1,* -- INTRODUCTION -- METHODOLOGY -- Data Collection and Sequence Alignment -- Phylogenetic Analysis -- Selection Pressure Analyses -- Analysis of Shannon Entropy -- Glycosylation Analysis -- RESULTS -- Phylogenetic Analysis and Genetic Distance Estimation -- Selection Pressure Analysis -- Shannon Entropy Analysis -- N-linked and O-linked Glycosylation -- DISCUSSION -- CONCLUDING REMARKS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Global Epidemiology and Transmission of COVID-19 -- Md. Wasim Khan1,#, Sajda Ara1,#, Farah Deeba1, Ayesha Tazeen1, Nasir Salam2, Irshad H. Naqvi3 and Shama Parveen1,* -- INTRODUCTION -- THE SPREAD -- INCREASE IN INFECTIVITY OF SARS-COV-2 -- THE SPILLOVER ZOONOTIC EVENTS -- TRANSMISSION -- Droplet and Aerosol Mediated Transmission. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Airborne Transmission -- Faecal Transmission -- Vertical Transmission -- Fomites Transmission -- Familial Transmission -- Nosocomial Transmission -- CONCLUDING REMARKS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFRENCES -- Risk Factors for Severe Covid-19 Disease -- Mohammad Misbah Urrehmaan1,2, Abu Hamza2, Zoya Shafat2, Saba Parveen2, Saima Wajid1,* and Shama Parveen2,* -- INTRODUCTION -- RISK FACTORS FOR SEVERE COVID-19 INFECTION -- Age Distribution -- Gender -- Blood Groups -- Comorbid Conditions -- Pre-natal Transmission -- CONCLUDING REMARKS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Clinical Manifestations, Treatment, Immune Response and Pathogenesis of Covid-19 -- Irshad H. Naqvi1,*, Md. Imam Faizan2,3, Mohammad Islamuddin2, Mohd Abdullah1, Arpita Rai4 and Shama Parveen2,* -- INTRODUCTION -- CLINICAL MANIFESTATIONS -- Incubation Period -- Transmission of Disease -- Quarantine and Isolation -- Peculiar Course of COVID-19 -- CLINICAL MANAGEMENT -- Oxygen Therapy: The First Step -- Symptomatic or Pre-symptomatic Infection -- Mild Illness -- Moderate Illness -- Clinical Management of Moderate Disease -- SEVERE CASES MANAGEMENT -- Urgent Supportive Therapy with Dedicated Monitoring -- Management of Respiratory Failure with Acute Respiratory Distress Syndrome (ARSD) -- Management of Extrapulmonary Manifestations and Systemic Complications -- Management of Septic Shock -- Other Therapeutic Measures -- NEW INVESTIGATIONAL THERAPIES -- Anti-Viral Drugs -- Tocilizumab -- Hydroxychloroquine -- Anticoagulant -- Convalescent Plasma -- Dexamethasone -- IMMUNE RESPONSE IN COVID-19 -- Innate Immune Response -- Adaptive Immune Response -- Potential Immune Evasion -- PATHOGENESIS -- CONCLUDING REMARKS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | COVID-19: Current Diagnostic Approaches -- Anwar Ahmed1,2,*, Fahad N. Almajhdi1,5, Md. Imam Faizan3,4, Tanveer Ahmad3 and Shama Parveen4,* -- INTRODUCTION -- SAMPLE COLLECTION -- REAL-TIME REVERSE TRANSCRIPTASE-PCR (RT-PCR) -- LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) -- SEROLOGICAL DIAGNOSIS -- RAPID DIAGNOSTIC TEST (RDT) -- ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) -- CHEMILUMINESCENT IMMUNOASSAY (CLIA) -- NEUTRALIZATION ASSAY (NA) -- RAPID ANTIGEN DETECTION TEST (RADT) -- CONCLUDING REMARKS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Natural Compounds as Potential Therapeutic Agents against COVID-19 -- Ayesha Tazeen1, Farah Deeba1, Zoya Shafat1, Md. Imam Faizan1,2, Maryam Sarwat3, Mohammad Khalid Parvez4 and Shama Parveen1,* -- INTRODUCTION -- SIGNIFICANCE OF PLANTS DERIVED COMPOUNDS AS ANTIVIRALS -- ANTIVIRAL ACTIVITY OF SELECTED NATURAL COMPOUNDS AGAINST SARS-COV-2 -- FLAVONOIDS -- Myricitrin -- Baicalin -- Hesperidin -- Theaflavin -- Quercetagetin -- Apigenin -- Glabridin -- TERPENES AND TERPENOIDS -- CURCUMINOIDS -- TANNIN -- PROMISING ANTIVIRAL POTENTIALS OF PLANTS -- Camellia Sinensis (Black/Oolong/Green Tea) -- Vitis vinifera (Grapevine or Black grapes) -- Malus domestica (Apple) -- Azadirachta indica (Neem) -- Glycyrrhiza glabra (Licorice) -- Nigella sativa (Black Seed) -- CONCLUDING REMARKS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- Drug Repurposing Candidates and Therapeutic Approaches towards the Treatment of COVID-19 -- Arshi Islam1, Nazish Parveen1, Abu Hamza1, Nazim Khan1, Syed Naqui Kazim1, Anwar Ahmed2,3 and Shama Parveen1,* -- INTRODUCTION -- The Available Therapeutic Options -- Strategies for the Development of an Antiviral Drug -- REMDESIVIR -- LOPINAVIR/RITONAVIR (LPV/RTV) -- CHLOROQUINE/HYDROXYCHLOROQUINE -- FAVIPIRAVIR. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | UMIFENOVIR (ARBIDOL) -- CONCLUDING REMARKS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- COVID-19 Vaccine Development: Challenges and Current Scenarios -- Nazish Parveen1, Arshi Islam1, Nazim Khan1, Anwar Ahmed2,3, Irshad H. Naqvi4 and Shama Parveen1,* -- INTRODUCTION -- VACCINES -- OBSTACLES IN THE IMPLEMENTATION OF COVID-19 VACCINE -- ANTIGEN SELECTION FOR VACCINE DEVELOPMENT -- ONGOING VACCINE DEVELOPMENT FOR COVID-19 -- Viral Vector Vaccine -- Sputnik-V (Approved for Early Use) -- Ad5-nCoV (Approved for Limited Use) -- AZD1222 -- Janssen Vaccine -- GRAd-COV2 -- LV-SMENP-DC -- aAPC -- Whole Virus Vaccines -- CoronaVac (Approved for Limited Use) -- Inactivated Novel Coronavirus Pneumonia Vaccine -- BBIBP-CorV -- Inactivated SARS-CoV-2 Vaccine -- COVAXIN -- QazCovid -- Nucleic acid vaccines -- mRNA-1273 -- BNT162 -- Self-amplifying RNA Vaccine for COVID-19 -- CVnCoV -- GX-19 -- INO-4800 DNA Vaccine -- AG0301-COVID19 -- bacTRL-Spike -- Zydus Cadila DNA Vaccine -- Subunit Vaccines -- Recombinant subunit vaccine for COVID-19 -- NVX-CoV2373 -- COVAX-19 -- SCB-2019 -- Soberana1 -- EpiVacCorona -- Virus Like Particle (VLP) Based Vaccine -- Tuberculosis Vaccine in Clinical Trial -- BCG vaccine -- VPM1002 Vaccine -- Vaccine Candidates in Preclinical Trial -- CONCLUDING REMARKS -- CONSENT FOR PUBLICATION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Subject Index -- Back Cover. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Coronavirus infections. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Parveen, Shama |
| Title | The COVID-19 Pandemic: Epidemiology, Molecular Biology and Therapy |
| Place, publisher, and date of publication | Singapore : Bentham Science Publishers,c2021 |
| International Standard Book Number | 9789811481857 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=6512661">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=6512661</a> |
| Public note | Click to View |
No items available.